• About
• Links
• Contact
• Sitemap
• 

Non-Hodgkin's Lymphoma (NHL) - Drug Pipeline Analysis and Market Forecasts to 2015

Summary

The report is an essential source of information and analysis on the global NHL market. The report identifies the key trends shaping and driving the global NHL market, a key segment within the pharma industry. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring significant shift in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global NHL sector.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by team of industry experts.

Scope

The scope of the report includes:

Annualized global Non-Hodgkin's Lymphoma (NHL) market revenues data from 2000 to 2008, forecast forward for 7 years to 2015.

Geographic markets covered in this report include the US, the UK, Italy, Spain, Germany, France, and Japan.

Pipeline analysis data providing a split across different phases, mechanism of action being developed and emerging trends.

Analysis of the current and future market competition in the global NHL market. Key market players covered include Genentech, Inc., GSK, Eli Lilly and Company, Pfizer Inc/ Wyeth, Novartis AG, and Biogen Idec.

Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Key topics covered include strategic competitor assessment, market characterization, unmet needs and implications for future market associated with NHL.

Reasons to buy

The report will enhance your decision making capability in a more rapid and time sensitive manner. It will allow you to:

Develop and design your in-licensing and out-licensing strategies through review of pipeline products and technologies and by identifying companies with the most robust pipeline.

Develop business strategies by understanding the trends shaping and driving the global NHL disease market.

Drive revenues by understanding key trends, innovative products and technologies, market segments and companies likely to impact the global NHL disease market in future.

Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

What’s the next big thing in the global NHL disease market landscape? – Identify, understand and capitalize.

Table of Contents

1 Table of contents 3

• 1.1 List of Tables 5
• 1.2 List of Figures 5

2 Non-Hodgkin’s Lymphoma Market: Market Characterization 6

• 2.1 Overview 6
• 2.2 Non-Hodgkin’s Lymphoma Market Size 6
• 2.3 Non-Hodgkin’s Lymphoma Market Forecast and CAGR 7
• 2.4 Drivers and Barriers for Non-Hodgkin’s Lymphoma Market 7
  • 2.4.1 Drivers for Non-Hodgkin’s Lymphoma Market 8
  • 2.4.2 Barrier for Non-Hodgkin’s Lymphoma Market 9
• 2.5 Opportunity and Unmet Need 9
• 2.6 Key Take Away 10

3 Non-Hodgkin’s Lymphoma Market: Competitive Assessment 11

• 3.1 Overview 11
• 3.2 Strategic Competitor Assessment 11
• 3.3 Product Profile for the Major Marketed Products in the Non-Hodgkin’s Lymphoma Market 12
  • 3.3.1 Rituxan (MabThera) 12
  • 3.3.2 Velcade® 14
  • 3.3.3 Bexxar 15
  • 3.3.4 Zevalin 16
  • 3.3.5 Treanda 18
  • 3.3.6 Campath (MabCampath or Campath-1H) 19
• 3.4 Recently Approved NHL Drugs for Non-Hodgkin’s Lymphoma 20
  • 3.4.1 Folotyn 20
  • 3.4.2 Mozobil 21
• 3.5 Key Take Away 24

4 Non-Hodgkin’s Lymphoma Market: Pipeline Assessment 25

• 4.1 Overview 25
• 4.2 Strategic Pipeline Assessment 25
  • 4.2.1 Technology Trends Analytical Framework 25
• 4.3 Non-Hodgkin’s Lymphoma Therapeutics – Promising Drugs under Clinical Development 27
• 4.4 Molecule Profile for Promising Drugs under Clinical Development 28
  • 4.4.1 BiovaxID 28
  • 4.4.2 Afinitor 29
  • 4.4.3 Reviroc 30
  • 4.4.4 Ontak 30
  • 4.4.5 LY317615 31
• 4.5 Non-Hodgkin’s Lymphoma Therapeutic Market – Clinical Pipeline by Mechanism of Action 32
• 4.6 Non-Hodgkin’s Lymphoma Pipeline –Pipeline by Phases of Development 33
  • 4.6.1 Non-Hodgkin’s Lymphoma Monotherapies and Combination Therapies Pipeline– Phase III Clinical Studies 34
  • 4.6.2 Non-Hodgkin’s Lymphoma Monotherapies and Combination Therapies Pipeline – Phase II Clinical Trials 35
  • 4.6.3 Non-Hodgkin’s Lymphoma Monotherapies and Combination Therapies Pipeline – Phase I Clinical Studies 43
  • 4.6.4 Non-Hodgkin’s Lymphoma Monotherapies and Combination Therapies Pipeline– Preclinical Studies 47
• 4.7 Discontinued/ Suspended Drugs for Non-Hodgkin’s Lymphoma 47
• 4.8 Key Take Away 49

5 Non-Hodgkin’s Lymphoma Market: Implications for Future Market Competition 51

6 Non-Hodgkin’s Lymphoma Market: Future Players in Non-Hodgkin’s Lymphoma Market 53

• 6.1 Introduction 53
• 6.2 Genentech, Inc. (Roche) 54
  • 6.2.1 Company Overview 54
  • 6.2.2 Business Description 54
  • 6.2.3 Company Pipeline 55
• 6.3 GlaxoSmithKline plc. (GSK) 60
  • 6.3.1 Company Overview 60
  • 6.3.2 Business Description 61
  • 6.3.3 Company Pipeline 61
• 6.4 Immunomedics, Inc. 63
  • 6.4.1 Company Overview 63
  • 6.4.2 Business Description 63
  • 6.4.3 Company Pipeline 64
• 6.5 Allos Therapeutics, Inc. 65
  • 6.5.1 Company Overview 65
  • 6.5.2 Business Description 65
  • 6.5.3 Company Pipeline 66
• 6.6 Seattle Genetics, Inc. 66
  • 6.6.1 Company Overview 66
  • 6.6.2 Business Description 67
  • 6.6.3 Company Pipeline 67
• 6.7 Eli Lilly and Company 68
  • 6.7.1 Company Overview 68
  • 6.7.2 Business Description 69
  • 6.7.3 Company Pipeline 69
• 6.8 Pfizer Inc. (Wyeth) 71
  • 6.8.1 Company Overview 71
  • 6.8.2 Business Description 71
  • 6.8.3 Company Pipeline 72
• 6.9 Novartis 74
  • 6.9.1 Company Overview 74
  • 6.9.2 Business Description 75
  • 6.9.3 Company Pipeline 75
• 6.10 Biogen Idec 77
  • 6.10.1 Company Overview 77
  • 6.10.2 Business Description 77
  • 6.10.3 Company Pipeline 77
• 6.11 Genzyme Corporation 78
  • 6.11.1 Company Overview 78
  • 6.11.2 Business Description 78
  • 6.11.3 Company Pipeline 79

7 Non-Hodgkin’s Lymphoma Market: Appendix 80

• 7.1 Definitions 80
• 7.2 Abbreviations 80
• 7.3 Research Methodology 81
  • 7.3.1 Coverage 82
  • 7.3.2 Secondary Research 82
  • 7.3.3 Forecasting 83
  • 7.3.4 Primary Research 85
  • 7.3.5 Expert Panel validation 86
• 7.4 Contact Us 86
• 7.5 Disclaimer 86
• 7.6 Sources 87

1.1 List of Tables

• Table 1: Non-Hodgkin’s Lymphoma Market, Global, Revenues ($m), 2000–2008 7
• Table 2: Non-Hodgkin’s Lymphoma Market, Global, Revenues ($m), 2008–2015 7
• Table 3: Major Marketed Products Comparison in Non-Hodgkin’s Lymphoma Market, 2010 22
• Table 4: Non-Hodgkin’s Lymphoma Therapeutics – Most Promising Drugs in Clinical Development, 2010 27
• Table 5: Non-Hodgkin’s Lymphoma Monotherapies Pipeline – Phase III Clinical Studies, 2010 34
• Table 6: Non-Hodgkin’s Lymphoma Combination Therapeutics Pipeline– Phase III Clinical Studies, 2010 35
• Table 7: Non-Hodgkin’s Lymphoma Monotherapies Pipeline – Phase II Clinical Studies, 2010 35
• Table 8: Non-Hodgkin’s Lymphoma Combination Therapies Pipeline– Phase II Clinical Studies, 2010 39
• Table 9: Non-Hodgkin’s Lymphoma Monotherapies Pipeline – Phase I Clinical Studies, 2010 43
• Table 10: Non-Hodgkin’s Lymphoma Combination Therapies Pipeline – Phase I Clinical Studies, 2010 46
• Table 11: Non-Hodgkin’s Lymphoma Mono Therapeutics and Combination Therapeutics Pipeline– Preclinical Studies, 2010 47
• Table 12: List of Discontinued/Suspended Drugs for Non-Hodgkin’s Lymphoma, 2010 47
• Table 13: F. Hoffmann-La Roche Ltd.- Oncology Pipeline Products, 2010 56
• Table 14: F. Hoffmann-La Roche Ltd. - Non-Hodgkin’s Lymphoma Pipeline Products, 2010 59
• Table 15: Genentech Inc. – Oncology Product Pipeline, 2010 60
• Table 16: Genentech Inc. – Non-Hodgkin’s Lymphoma Product Pipeline, 2010 60
• Table 17: GlaxoSmithKline plc. – Oncology Product Pipeline, 2010 62
• Table 18: GlaxoSmithKline plc. – Non-Hodgkin’s Lymphoma Product Pipeline, 2010 63
• Table 19: Immunomedics, Inc. – Oncology Product Pipeline, 2010 64
• Table 20: Immunomedics, Inc. – Non-Hodgkin’s Lymphoma Product Pipeline, 2010 65
• Table 21: Allos Therapeutics, Inc – Oncology Product Pipeline, 2010 66
• Table 22: Allos Therapeutics, Inc – Non-Hodgkin’s Lymphoma Product Pipeline, 2010 66
• Table 23: Seattle Genetics, Inc. – Oncology Product Pipeline, 2010 68
• Table 24: Seattle Genetics, Inc. – Non-Hodgkin’s Lymphoma Product Pipeline, 2010 68
• Table 25: Eli Lilly and Company – Oncology Product Pipeline, 2010 70
• Table 26: Eli Lilly and Company – Non-Hodgkin’s Lymphoma Product Pipeline, 2010 71
• Table 27: Pfizer Inc. (Wyeth) – Oncology Product Pipeline, 2010 73
• Table 28: Pfizer Inc. (Wyeth) – Non-Hodgkin’s Lymphoma Product Pipeline, 2010 74
• Table 29: Novartis – Oncology Product Pipeline, 2010 76
• Table 30: Novartis – Non-Hodgkin’s Lymphoma Product Pipeline, 2010 77
• Table 31: Biogen Idec – Oncology Product pipeline, 2010 78
• Table 32: Biogen Idec – Non-Hodgkin’s Lymphoma Product pipeline, 2010 78
• Table 33: Genzyme Corporation – Oncology Product pipeline, 2010 79
• Table 34: Genzyme Corporation – Non-Hodgkin’s Lymphoma Product pipeline, 2010 79

1.2 List of Figures

• Figure 1: Global Non-Hodgkin’s Lymphoma Market Forecast ($m), 2000-2015 7
• Figure 2: Opportunity and Unmet Need in the Non-Hodgkin’s Lymphoma Market, 2010 9
• Figure 3: Strategic Competitor Assessment, 2010 12
• Figure 4: Technology Trends Analytic Framework – Non-Hodgkin’s Lymphoma Market, 2010 26
• Figure 5: Technology Trends Analytic Framework of the Rheumatoid Arthritis Pipeline – Description, 2010 26
• Figure 6: Non-Hodgkin’s Lymphoma Therapeutics Market – Clinical Pipeline by Mechanism of Action, 2010 33
• Figure 7: Non-Hodgkin’s Lymphoma Pipeline by Phase of Clinical Development, 2010 33
• Figure 8: Implications for Future Market Competition in Non-Hodgkin’s Lymphoma, 2010 51
• Figure 9: Non-Hodgkin’s Lymphoma Therapeutics Market – Clinical Pipeline by Company, 2010 53
• Figure 10: Non-Hodgkin’s Lymphoma Market, Global–Companies Having Highest Number of Molecules in Pipeline, 2010 54
• Figure 11: Methodology 82
• Figure 12: Market Forecasting Model 85

Other users found this report page using the following search terms: lymphoma nhl lymphoma market marketsizefornonhodgkinslymphomaanduk pipeline nhl hodgkins size non nonhodgkins nonhodgkinslymphomapipeline

If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.

Refund and Cancellation Policy: The descriptions of the products and services sold on LeadDiscovery.co.uk are as complete and accurate as possible, and customers are encouraged to read all available information about a product before placing an order. Due to the nature of the information being sold, orders for reports cannot be canceled.